Inovio Pharmaceuticals announced its early-stage trial to assess its HIV vaccine PENNVAX GP had achieved positive preliminary results, indicating that the vaccine produced durable, robust immune responses in the participants six months after they were given the last dose. The data was presented at the HIV Vaccine Trials Network meeting.
Inovio reports on Phase I data from HIV vaccine PENNVAX GP trial
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.